PO.BCS02.05 · 生物信息与计算

Genie-ADLA: A deep learning algorithm for methylation-based multiple cancer early detection (MCED)

海报缩略图:Genie-ADLA: A deep learning algorithm for methylation-based multiple cancer early detection (MCED)
编号 5471 展板 7 时间 4/21 02:00–05:00 区域 Section 2 主讲 Guoqiang Zhao, MS
分会场 Deep Learning in Cancer
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Kezhong Chen1, Ziyu Li2, Xiaojian Wu3, Jian Huang4, Guoyue Lv5, Weiping Wen6, Dahong Zhang7, Xiangyu Zhao8, Danbo Wang9, Zhihua Liu10, Lixin Sun11, Shu Wang12, Xiangnan Li13, Zhigang Li14, Jiandong Tai15, Jiayin Yang16, Zhentong Wei17, Ming Cai18, Qiang Zhang9, Songbing He19, Shuhua Yi20, Shenhong Qu21, Wenhui Zhao22, Xianjun Yu23, Ruixia Guo13, Jianhong Lian11, Desong Yang24, Huaiwu Lu25, Xi Guo26, Yan Zhang27, Zhuowei Liu28, Yingjiang Ye29, Chang Lin30, Jie Gao31, Xuanhui Liu32, Yushu Guo33, Suying Ding13, Guoqiang Zhao34, Yanzhan Yang34, Jiangyu Li34, Shiqing Chen34, Hui Yu34, Fang Liu34, Yang Wang34, Min Li34, Baoliang Zhu34, Yonghui Li34, Xiaohui Wu34, Fan Yang1, Jun Wang1

1Thoracic Oncology Institute and Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China,2Peking University Cancer Hospital and Institute, Beijing, China,3Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,4The Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,5Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China,6Department of Otolaryngology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,7Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China,8Peking University People's Hospital, Peking Universtiy Institute of Hematology, Beijing, China,9Liaoning Provincial Cancer Hospital, Shenyang, China,10Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China,11Department of General Surgery, Shanxi Cancer Hospital, Taiyuan, China,12Breast Disease Center, Peking University People's Hospital, Beijing, China,13The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,14Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of medicine, Shanghai, China,15Department of Colorectal&anal Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China,16The Department of Liver Surgery of West China Hospital, Sichuan University, Chengdu, China,17Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China,18Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China,19The First Affiliated Hospital of Soochow University Department of General Surgery, Suzhou, China,20National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China,21Department of Otolaryngology-Head and Neck Surgery, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, China,22Harbin Medical University Cancer Hospital, Harbin, China,23Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,24Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,25Department of Gynecologic Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China,26Department of Urology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China,27Department of Oncology, Shijiazhuang People’s Hospital, Shijiazhuang, China,28Sun Yat-sen University Cancer Center, Guangzhou, China,29Department of Gastrointestinal Surgery, Peking University People's Hospital, Beijing, China,30Otorhinolaryngology Department of the First Affiliated Hospital of Fujian Medical University, Fuzhou, China,31Department of Hepatobiliary Surgery, Peking University Organ Transplantation Institute, Peking University People's Hospital, Beijing, China,32The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,33Health Management Center, Peking University People’s Hospital, Beijing, China,34Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China

摘要 Abstract

Background: Methylation-based analysis of cell-free DNA (cfDNA) has emerged as a key technology for MCED. However, existing approaches rely on traditional machine learning algorithms, which inherently limit detection performance. With the rapid advancement of artificial intelligence (AI), we have developed Genie-ADLA, a deep learning algorithm designed specifically for MCED. By integrating state-of-the-art deep neural network architectures with the intrinsic patterns inherent in methylation data, Genie-ADLA significantly enhanced MCED performance. Methods: Genie-ADLA was trained and evaluated on a dataset of 4,781 participants aged 40-75 years, including 2,702 pathologically confirmed cancer cases across 16 cancer types and 2,079 non-cancer controls (NCT06217900). The training set comprised 3,217 samples (1,756 cancer cases and 1,461 non-cancer controls), and the model's performance was evaluated on an independent test set of 1,564 samples (618 non-cancer controls and 946 cancer cases). To address challenges inherent to methylation data-high dimensionality, sparsity, and noise-we applied feature dimensionality reduction and embedding strategies, reducing computational burden, mitigating overfitting, and improving learning efficiency. An ensemble learning approach further strengthened robustness and generalization. Results: Across all stages of 16 cancer types, Genie-ADLA achieved an overall sensitivity of 63.43% (600/946, 95% CI: [60.26%, 66.50%]) at 99.3% (612/618, 95% CI: [97.90%, 99.64%]) specificity in the test cohort. Compared with the XGBoost model trained on the same dataset, Genie-ADLA demonstrated improved overall sensitivity in 11 of the 16 cancer types, with an average increase of 4.86%.For stage I-III cancer patients, the sensitivities at 99.3% specificity showed notable gains over XGBoost: colorectal cancer achieved 76.98% (97/126, 95% CI: [68.65%, 84.01%]), an improvement of 9.52% from 67.46%; esophageal cancer reached 80.95% (51/63, 95% CI: [69.09%, 89.75%]), up 6.35% from 74.60%; breast cancer reached 37.14% (26/70, 95% CI: [25.89%, 49.52%]), improving by 5.71% from 31.43%. Lung cancer was subdivided into adenocarcinoma and non-adenocarcinoma, with stage I-III sensitivities of 40.90% (27/66, 95% CI: [28.95%, 53.71%]) in adenocarcinoma, an increase of 10.6%, and 84.44% (38/45, 95% CI: [70.54%, 93.51%]) in non-adenocarcinoma, improving by 2.22%. Conclusions: Genie-ADLA, leveraging advanced deep neural network architectures and data processing strategies, substantially elevates the performance ceiling of methylation-based early cancer detection, offering a new paradigm for AI-driven cancer screening.
利益披露 Disclosure
K. Chen, None.. Z. Li, None.. X. Wu, None.. J. Huang, None.. G. Lv, None.. W. Wen, None.. D. Zhang, None.. X. Zhao, None.. D. Wang, None.. Z. Liu, None.. L. Sun, None.. S. Wang, None.. X. Li, None.. Z. Li, None.. J. Tai, None.. J. Yang, None.. Z. Wei, None.. M. Cai, None.. Q. Zhang, None.. S. He, None.. S. Yi, None.. S. Qu, None.. W. Zhao, None.. X. Yu, None.. R. Guo, None.. J. Lian, None.. D. Yang, None.. H. Lu, None.. X. Guo, None.. Y. Zhang, None.. Z. Liu, None.. Y. Ye, None.. C. Lin, None.. J. Gao, None.. X. Liu, None.. Y. Guo, None.. S. Ding, None. G. Zhao, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. Y. Yang, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. J. Li, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. S. Chen, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. H. Yu, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. F. Liu, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. Y. Wang, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. M. Li, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. B. Zhu, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. Y. Li, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. X. Wu, Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment. F. Yang, None.. J. Wang, None.

在会议检索中打开